Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:NSCLC molecular testing in Central and Eastern European countries
Authors:Ryška, Ales (Author)
Berzinec, Peter (Author)
Brčić, Luka (Author)
Čufer, Tanja (Author)
Dziadziuszko, Rafal (Author)
Gottfried, Maya (Author)
Kovalszky, Ilona (Author)
Olszewski, Włodzimierz (Author)
Oz, Buge (Author)
Plank, Lukas (Author)
Tímár, József (Author)
Language:English
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines. Methods: A questionnaire about molecular testing and NSCLC management was distributed to relevant specialists in nine CEE countries, and pathologists were asked to provide the results of EGFR and ALK testing over a 1-year period. Results: A very high proportion of lung cancer cases are confirmed histologically/cytologically (75-100%), and molecular testing of NSCLC samples has been established in all evaluated CEE countries in 2014. Most countries follow national or international guidelines on which patients to test for EGFR mutations and ALK rearrangements. In most centers at that time, testing was undertaken on request of the clinician rather than on the preferred reflex basis. Immunohistochemistry, followed by fluorescent in situ hybridization confirmation of positive cases, has been widely adopted for ALK testing in the region. Limited reimbursement is a significant barrier to molecular testing in the region and a disincentive to reflex testing. Multidisciplinary tumor boards are established in most of the countries and centers, with 75-100% of cases being discussed at a multidisciplinary tumor board at specialized centers. Conclusions: Molecular testing is established throughout the CEE region, but improved and unbiased reimbursement remains a major challenge for the future. Increasing the number of patients reviewed by multidisciplinary boards outside of major centers and access to targeted therapy based on the result of molecular testing are other major challenges.
Keywords:non-small-cell lung carcinoma, molecular diagnostic techniques, EGFR mutations, ALK rearrangements, Central Europe, Eastern Europe
Year of publishing:2018
Publisher:Springer Nature
Source:Velika Britanija
COBISS_ID:2048273521 Link is opened in a new window
UDC:616-006
ISSN on article:1471-2407
OceCobissID:2434324 Link is opened in a new window
DOI:10.1186/s12885-018-4023-4 Link is opened in a new window
Note:Soavtorji: Peter Berzinec, Luka Brcic, Tanja Cufer, Rafal Dziadziuszko, Maya Gottfried, Ilona Kovalszky, Włodzimierz Olszewski, Buge Oz, Lukas Plank in Jozsef Timar; Nasl. z nasl. zaslona; Opis vira z dne 12. 4. 2018;
Views:852
Downloads:421
Files:.pdf PDF - Presentation file, download (373,86 KB)
URL URL - Source URL, visit https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-4023-4.pdf
 
Journal:BMC Cancer
BioMed Central
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© The Author(s). 2018
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:09.03.2018

Back